Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT02221739 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT02221739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02221739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
NYU Langone Health
Phase
Phase 1/2
Overall status
Completed
Start date
July 1, 2014
Completion date
October 27, 2015
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)